A minimum of three vaccine efforts have reached Part three medical trials in America and Europe, which is the final stage of human testing for brand new medication. If profitable, the vaccine candidates from Moderna, Pfizer/BioNTech, and AstraZeneca/Oxford might obtain emergency use authorization this yr, as early as October and ...